nach oben

Erschienen in:

19.10.2015 | Original Article

Effects of silibinin on growth and invasive properties of human ovarian carcinoma cells through suppression of heregulin/HER3 pathway

verfasst von: Majid Momeny, Reza Ghasemi, Giovanni Valenti, Mariska Miranda, Ali Zekri, Ghazaleh Zarrinrad, Sepehr Javadikooshesh, Marjan Yaghmaie, Kamran Alimoghaddam, Ardeshir Ghavamzadeh, Seyed H. Ghaffari

Erschienen in: Tumor Biology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Epithelial ovarian cancer (EOC) is the most fatal gynecological malignancy due to its high proliferative and invasive capacities. A heregulin (HRG)/HER3 autocrine loop increases proliferative and metastatic properties of EOC cells, suggesting that modulators of this signaling pathway may prove effective to trammel growth and motility of these cells. This study aimed to evaluate the effects of multi-tyrosine kinase inhibitor silibinin on proliferative and invasive characteristics of EOC cell lines OVCAR8 and SKOV3 through suppression of the HRG/HER3 pathway. To achieve this, the effects of silibinin on proliferation, DNA synthesis, clonogenicity, cell cycle progression, cathepsin B enzymatic activity, and migration and invasion were explored in vitro. Silibinin suppressed proliferation, DNA synthesis, and clonogenic abilities of OVCAR8 and SKOV3 cells through inhibition of the autocrine HRG/HER3 circuit. Silibinin-mediated attenuation of the HER3 signaling disabled the HER3/AKT/survivin axis and thereby, induced G1/S cell cycle arrest. Furthermore, silibinin reduced invasive potentials of the EOC cells through quelling the HRG/HER3 pathway and suppression of cathepsin B activity. Altogether, these results suggest that silibinin is a potential anti-cancer drug to inhibit proliferative and invasive characteristics of the EOC cells that exhibit an autocrine HRG/HER3 pathway.

Nur mit Berechtigung zugänglich

Bowtell DD. The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer. 2010;10(11):803–8.CrossRefPubMed

Dinh P et al. New therapies for ovarian cancer: cytotoxics and molecularly targeted agents. Crit Rev Oncol Hematol. 2008;67(2):103–12.CrossRefPubMed

Siwak DR et al. Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J Oncol. 2010;2010:568938.CrossRefPubMed

Garrett JT et al. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci U S A. 2011;108(12):5021–6.CrossRefPubMedPubMedCentral

Tzahar E et al. A hierarchical network of interreceptor interactions determines signal transduction by neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol. 1996;16(10):5276–87.CrossRefPubMedPubMedCentral

Amin DN, Campbell MR, Moasser MM. The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol. 2010;21(9):944–50.CrossRefPubMedPubMedCentral

Gala K, Chandarlapaty S. Molecular pathways: HER3 targeted therapy. Clin Cancer Res. 2014;20(6):1410–6.CrossRefPubMedPubMedCentral

Engelman JA et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316(5827):1039–43.CrossRefPubMed

Momeny M et al. Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines. Oncotarget. 2015;6(6):3932–46.CrossRefPubMedPubMedCentral

10.

Berchuck A et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 1990;50(13):4087–91.PubMed

11.

Tanner B et al. ErbB-3 predicts survival in ovarian cancer. J Clin Oncol. 2006;24(26):4317–23.CrossRefPubMed

12.

Pradeep S et al. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell. 2014;26(1):77–91.CrossRefPubMedPubMedCentral

13.

Momeny M et al. Silibinin inhibits invasive properties of human glioblastoma U87MG cells through suppression of cathepsin B and nuclear factor kappa B-mediated induction of matrix metalloproteinase 9. Anticancer Drugs. 2010;21(3):252–60.CrossRefPubMed

14.

Tyagi A et al. Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages. Carcinogenesis. 2004;25(9):1711–20.CrossRefPubMed

15.

Kumar S et al. Silibinin strongly inhibits the growth kinetics of colon cancer stem cell-enriched spheroids by modulating interleukin 4/6-mediated survival signals. Oncotarget. 2014;5(13):4972–89.CrossRefPubMedPubMedCentral

16.

Chu SC et al. Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Mol Carcinog. 2004;40(3):143–9.CrossRefPubMed

17.

Zhou L et al. Silibinin restores paclitaxel sensitivity to paclitaxel-resistant human ovarian carcinoma cells. Anticancer Res. 2008;28(2A):1119–27.PubMed

18.

Nambiar DK, et al. Silibinin inhibits aberrant lipid metabolism, proliferation and emergence of androgen-independence in prostate cancer cells via primarily targeting the sterol response element binding protein 1. Oncotarget. 2014.

19.

Momeny M et al. Effects of silibinin on cell growth and invasive properties of a human hepatocellular carcinoma cell line, HepG-2, through inhibition of extracellular signal-regulated kinase 1/2 phosphorylation. Eur J Pharmacol. 2008;591(1-3):13–20.CrossRefPubMed

20.

Hsieh YS et al. Silibinin suppresses human osteosarcoma MG-63 cell invasion by inhibiting the ERK-dependent c-Jun/AP-1 induction of MMP-2. Carcinogenesis. 2007;28(5):977–87.CrossRefPubMed

21.

Deep G, Agarwal R. Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev. 2010;29(3):447–63.CrossRefPubMedPubMedCentral

22.

Sheng Q et al. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell. 2010;17(3):298–310.CrossRefPubMedPubMedCentral

23.

Smith JA et al. An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines. Gynecol Oncol. 2005;98(1):141–5.CrossRefPubMed

24.

Franken NA et al. Clonogenic assay of cells in vitro. Nat Protoc. 2006;1(5):2315–9.CrossRefPubMed

25.

Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101–8.CrossRefPubMed

26.

Gilmour LM et al. Neuregulin expression, function, and signaling in human ovarian cancer cells. Clin Cancer Res. 2002;8(12):3933–42.PubMed

27.

Breuleux M. Role of heregulin in human cancer. Cell Mol Life Sci. 2007;64(18):2358–77.CrossRefPubMed

28.

Weiss FU et al. Distinct characteristics of heregulin signals mediated by HER3 or HER4. J Cell Physiol. 1997;173(2):187–95.CrossRefPubMed

29.

Bezler M, Hengstler JG, Ullrich A. Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells. Mol Oncol. 2012;6(5):516–29.CrossRefPubMed

30.

van der Horst EH, Weber I, Ullrich A. Tyrosine phosphorylation of PYK2 mediates heregulin-induced glioma invasion: novel heregulin/HER3-stimulated signaling pathway in glioma. Int J Cancer. 2005;113(5):689–98.CrossRefPubMed

31.

Shin I et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med. 2002;8(10):1145–52.CrossRefPubMed

32.

Gao N et al. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol. 2004;287(2):C281–91.CrossRefPubMed

33.

Xing H et al. Activation of fibronectin/PI-3K/Akt2 leads to chemoresistance to docetaxel by regulating survivin protein expression in ovarian and breast cancer cells. Cancer Lett. 2008;261(1):108–19.CrossRefPubMed

34.

Zhang HY, Zhang PN, Sun H. Aberration of the PI3K/AKT/mTOR signaling in epithelial ovarian cancer and its implication in cisplatin-based chemotherapy. Eur J Obstet Gynecol Reprod Biol. 2009;146(1):81–6.CrossRefPubMed

35.

Tran H et al. The many forks in FOXO’s road. Sci STKE. 2003;2003(172):RE5.PubMed

36.

Daly C et al. Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1). Genes Dev. 2004;18(9):1060–71.CrossRefPubMedPubMedCentral

37.

Brunet A et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999;96(6):857–68.CrossRefPubMed

38.

Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer. 2006;6(10):764–75.CrossRefPubMed

39.

Kozyreva EA et al. Prognostic significance of determining cathepsin B activity in malignant ovarian tumors. Vopr Med Khim. 1994;40(1):25–7.PubMed

40.

Warwas M et al. Cathepsin B-like activity as a serum tumour marker in ovarian carcinoma. Eur J Clin Chem Clin Biochem. 1997;35(4):301–4.PubMed

41.

Nishikawa H et al. The role of cathepsin B and cystatin C in the mechanisms of invasion by ovarian cancer. Gynecol Oncol. 2004;92(3):881–6.CrossRefPubMed

42.

Steffan JJ et al. Na+/H+ exchangers and RhoA regulate acidic extracellular pH-induced lysosome trafficking in prostate cancer cells. Traffic. 2009;10(6):737–53.CrossRefPubMed

43.

Sheng Q, Liu J. The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. Br J Cancer. 2011;104(8):1241–5.CrossRefPubMedPubMedCentral

44.

Lafky JM et al. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta. 2008;1785(2):232–65.PubMed

45.

Lee CH et al. Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma. Int J Gynecol Pathol. 2005;24(2):147–52.CrossRefPubMed

46.

Secord AA et al. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;108(3):493–9.CrossRefPubMedPubMedCentral

47.

Schilder RJ et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group study. Clin Cancer Res. 2005;11(15):5539–48.CrossRefPubMed

48.

Vergote IB et al. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. J Clin Oncol. 2014;32(4):320–6.CrossRefPubMed

49.

Meden H et al. Overexpression of the oncogene c-erb B2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression. Int J Gynecol Pathol. 1994;13(1):45–53.CrossRefPubMed

50.

Slamon DJ et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707–12.CrossRefPubMed

51.

Tuefferd M et al. HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS One. 2007;2(11):e1138.CrossRefPubMedPubMedCentral

52.

Xu F et al. The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression. Clin Cancer Res. 1999;5(11):3653–60.PubMed

53.

Ueno NT et al. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res. 2000;6(1):250–9.PubMed

54.

Bookman MA et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol. 2003;21(2):283–90.CrossRefPubMed

55.

Gordon MS et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol. 2006;24(26):4324–32.CrossRefPubMed

56.

Banerjee S, Kaye SB. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin Cancer Res. 2013;19(5):961–8.CrossRefPubMed

57.

Shen K, Lang J, Guo L. Overexpression of C-erbB3 in transitional cell carcinoma of the ovary. Zhonghua Fu Chan Ke Za Zhi. 1995;30(11):658–61.PubMed

58.

Leng J et al. Overexpression of p53, EGFR, c-erbB2 and c-erbB3 in endometrioid carcinoma of the ovary. Chin Med Sci J. 1997;12(2):67–70.PubMed

59.

Tsuda H et al. Identification of DNA copy number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platform. Cancer Genet Cytogenet. 2004;155(2):97–107.CrossRefPubMed

60.

Davies S et al. High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer. Int J Gynecol Pathol. 2014;33(4):402–10.CrossRefPubMedPubMedCentral

61.

Ocana A et al. HER3 overexpression and survival in solid tumors: a meta-analysis. J Natl Cancer Inst. 2013;105(4):266–73.CrossRefPubMed

62.

Campbell MR, Amin D, Moasser MM. HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res. 2010;16(5):1373–83.CrossRefPubMedPubMedCentral

63.

Shayesteh L et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet. 1999;21(1):99–102.CrossRefPubMed

64.

Meng Q et al. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell Signal. 2006;18(12):2262–71.CrossRefPubMed

65.

Page C et al. Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res. 2000;20(1A):407–16.PubMed

66.

Hu L et al. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res. 2002;62(4):1087–92.PubMed

67.

Sui L et al. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. Int J Oncol. 2002;21(2):315–20.PubMed

68.

Takai N et al. Expression of survivin is associated with malignant potential in epithelial ovarian carcinoma. Int J Mol Med. 2002;10(2):211–6.PubMed

69.

Xing J et al. Effect of shRNA targeting survivin on ovarian cancer. J Cancer Res Clin Oncol. 2012;138(7):1221–9.CrossRefPubMed

70.

Chakrabarty A et al. Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. Cancer Res. 2013;73(3):1190–200.CrossRefPubMed

Titel: Effects of silibinin on growth and invasive properties of human ovarian carcinoma cells through suppression of heregulin/HER3 pathway
verfasst von: Majid Momeny
Reza Ghasemi
Giovanni Valenti
Mariska Miranda
Ali Zekri
Ghazaleh Zarrinrad
Sepehr Javadikooshesh
Marjan Yaghmaie
Kamran Alimoghaddam
Ardeshir Ghavamzadeh
Seyed H. Ghaffari
Publikationsdatum: 19.10.2015
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 3/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-4220-6

Springer Medizin

Effects of silibinin on growth and invasive properties of human ovarian carcinoma cells through suppression of heregulin/HER3 pathway

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2016

Hyperfibrinogenemia predicts poor prognosis in patients with advanced biliary tract cancer

Methyl methanesulfonate induces necroptosis in human lung adenoma A549 cells through the PIG-3-reactive oxygen species pathway

Alanine aminotransferase to hemoglobin ratio is an indicator for disease progression for hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization

Apoptotic effects of salinomycin on human ovarian cancer cell line (OVCAR-3)

microRNA-188 is downregulated in oral squamous cell carcinoma and inhibits proliferation and invasion by targeting SIX1

The diagnostic utility of the triple markers Napsin A, TTF-1, and PAX8 in differentiating between primary and metastatic lung carcinomas

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie